Tech Company Financing Transactions
Orna Therapeutics Funding Round
Orna Therapeutics, based in Cambridge, secured $221 million from BioImpact Capital, Merck and MPM Capital.
Transaction Overview
Company Name
Announced On
8/17/2022
Transaction Type
Venture Equity
Amount
$221,000,000
Round
Series B
Investors
Proceeds Purpose
The company intends to use the funds to continue development of its circular RNA + LNP (lipid nanoparticle) delivery platform, as augmented by its joint venture with ReNAgade Therapeutics, an RNA delivery company created by MPM Capital and BioImpact Capital, to advance its lead in situ CAR (isCAR) program toward the clinic and build manufacturing capabilities to support development of an expanding preclinical and clinical pipeline.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
620 Memorial Dr. 2nd Floor
Cambridge, MA 02139
USA
Cambridge, MA 02139
USA
Phone
Undisclosed
Website
Email Address
Overview
Orna Therapeutics is leaving linear thinking behind to create fully engineered circular RNA (oRNA) therapeutics -- an entirely new class of RNA medicines that can realize the full potential of RNA and which is poised to change the way we treat disease.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Thomas Barnes
Chief Financial Officer
John McCabe
Vice President
Gregory Motz
VP - Bus. Development
Brian Goodman
Browse more venture capital transactions:
Prev: 8/17/2022: Agora Real Estate Technologies venture capital transaction
Next: 8/17/2022: Hibob venture capital transaction
Share this article
About Database of VC Transactions
Our team works diligently to report on funding rounds that are announced publicly. VC transactions on this site are sourced from company press releases and news coverage. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs